Investigating XXXX expression as a potential genomic biomarker of response to @entity310 inhibitor biologics in whole blood @entity309 samples.

@entity1 @entity2935 @entity310 @entity309
INTRODUCTION: Gene expression profiling is rapidly becoming a useful and informative tool in a much needed area of research. Identifying @entity1 as to whether they will respond or not to a given treatment before prescription is not only essential to optimise treatment outcome but also to lessen the economic burden that such drugs can have on healthcare resources. In @entity309 ( @entity309 ), there is of yet no genetic/genomic biomarker which can accurately predict response to @entity310 inhibitor biologics prior to treatment, despite much interest in this area. Multiple studies have reported findings on potential candidate genes; however, due to relatively small sample sizes or lack of sufficient validation, results have been disappointingly inconsistent. The aim of this research was to further explore the predictive value of a previously reported association between @entity2935 expression and response to the @entity310 inhibitor biologics, adalimumab and etanercept. METHODS: Real-time qPCR was performed using whole blood RNA samples obtained from seventy-five @entity309 @entity1 about to commence treatment with a @entity310 inhibitor biologic drug, whose response status was determined at 3-month follow-up using the EULAR classification criteria. Relative quantification of @entity2935 using the comparative CT method outputted differential expression between good-responders and non-responders as a fold-change. RESULTS: Relative expression of @entity2935 in @entity1 receiving @entity310 inhibitor biologics yielded a decrease of 1.025 fold in good-responders as compared to non-responders (p-value = 0.36). Upon stratification of @entity1 dependent upon the specific drug administered, adalimumab or etanercept, similar findings to the full cohort were observed, decreases of 1.015 (p-value = 0.33) and 1.032 fold (p-value = 0.13) in good-responders compared to non-responders, respectively. CONCLUSION: The results from this study reveal that @entity2935 expression does not correlate with response to @entity310 inhibitor biologics when tested for within pre-treatment whole blood samples of @entity309 @entity1 .
